Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Collegium Pharmaceutical (COLL) Long-Term Debt Issuances (2018 - 2023)

Collegium Pharmaceutical has reported Long-Term Debt Issuances over the past 3 years, most recently at -$434000.0 for Q2 2023.

For Q2 2023, Long-Term Debt Issuances changed N/A year-over-year to -$434000.0; the TTM value through Dec 2023 reached $235.2 million, changed N/A, while the annual FY2023 figure was $235.2 million, N/A changed from the prior year.
Long-Term Debt Issuances for Q2 2023 was -$434000.0 at Collegium Pharmaceutical, down from $235.7 million in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $235.7 million in Q1 2023 and troughed at -$53.8 million in Q4 2020.